New hope for blood cancer patients: experimental combo shows promise in Late-Stage trial
NCT ID NCT04246047
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard treatment for people with multiple myeloma that has come back or stopped responding to therapy. About 494 adults with this blood cancer will be randomly assigned to one of the two treatment groups. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Yuma, Arizona, 85364, United States
-
GSK Investigational Site
Denver, Colorado, 80218, United States
-
GSK Investigational Site
Kansas City, Kansas, 66205, United States
-
GSK Investigational Site
Fairfield, Ohio, 45242, United States
-
GSK Investigational Site
Tyler, Texas, 75702, United States
-
GSK Investigational Site
Liverpool, New South Wales, 2170, Australia
-
GSK Investigational Site
Wollongong, New South Wales, 2500, Australia
-
GSK Investigational Site
Benowa, Queensland, 4217, Australia
-
GSK Investigational Site
Brussels, 1090, Belgium
-
GSK Investigational Site
Brussels, 1200, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Roeselare, 8800, Belgium
-
GSK Investigational Site
Beijing, 100191, China
-
GSK Investigational Site
Jinan, 250012, China
-
GSK Investigational Site
Shenyang, 110001, China
-
GSK Investigational Site
Alexandroupoli, 68 100, Greece
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Thessaloniki, 54007, Greece
-
GSK Investigational Site
Tel Aviv, 64239, Israel
-
GSK Investigational Site
Bergamo, 24127, Italy
-
GSK Investigational Site
Meldola FC, 47014, Italy
-
GSK Investigational Site
Milan, 20133, Italy
-
GSK Investigational Site
Siena, 53100, Italy
-
GSK Investigational Site
Aichi, 441-8570, Japan
-
GSK Investigational Site
Aichi, 467-8602, Japan
-
GSK Investigational Site
Aomori, 030-8553, Japan
-
GSK Investigational Site
Ehime, 790-8524, Japan
-
GSK Investigational Site
Fukuoka, 806-8501, Japan
-
GSK Investigational Site
Fukuoka, 807-8555, Japan
-
GSK Investigational Site
Fukuoka, 810-8563, Japan
-
GSK Investigational Site
Fukuoka, 815-8555, Japan
-
GSK Investigational Site
Gifu, 503-8502, Japan
-
GSK Investigational Site
Gunma, 377-0280, Japan
-
GSK Investigational Site
Hyōgo, 670-8540, Japan
-
GSK Investigational Site
Kanagawa, 221-0855, Japan
-
GSK Investigational Site
Kanagawa, 247-8533, Japan
-
GSK Investigational Site
Kochi, 781-8555, Japan
-
GSK Investigational Site
Nagano, 392-8510, Japan
-
GSK Investigational Site
Okayama, 701-1192, Japan
-
GSK Investigational Site
Osaka, 530-0012, Japan
-
GSK Investigational Site
Osaka, 545-8586, Japan
-
GSK Investigational Site
Shizuoka, 411-8777, Japan
-
GSK Investigational Site
Dordrecht, 3318 AT, Netherlands
-
GSK Investigational Site
Groningen, 9713 GZ, Netherlands
-
GSK Investigational Site
Chorzów, 41-500, Poland
-
GSK Investigational Site
Krakow, 30510, Poland
-
GSK Investigational Site
Lodz, 93-513, Poland
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Lublin, 20-090, Poland
-
GSK Investigational Site
Nowy Sącz, 33-300, Poland
-
GSK Investigational Site
Poznan, 60-569, Poland
-
GSK Investigational Site
Warsaw, 02-781, Poland
-
GSK Investigational Site
Moscow, 125284, Russia
-
GSK Investigational Site
Nizhny Novgorod, 603126, Russia
-
GSK Investigational Site
Novosibirsk, 630087, Russia
-
GSK Investigational Site
Saint Petersburg, 191024, Russia
-
GSK Investigational Site
Saint Petersburg, 197 089, Russia
-
GSK Investigational Site
Saratov, 410028, Russia
-
GSK Investigational Site
Ufa, 450083, Russia
-
GSK Investigational Site
Pusan, 49241, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Barcelona, 08916, Spain
-
GSK Investigational Site
Cáceres, 10003, Spain
-
GSK Investigational Site
Gijón, 33394, Spain
-
GSK Investigational Site
L'Hospitalet de Llobrega, 08908, Spain
-
GSK Investigational Site
Murcia, 30008, Spain
-
GSK Investigational Site
PamplonaNavarra, 31008, Spain
-
GSK Investigational Site
Salamanca, 37007, Spain
Conditions
Explore the condition pages connected to this study.